Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.51 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 4/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211889 | 0.87 | P4HTM (0.59) | MAP4K4P4HTMP4HA1MIFKDM4E | |
| SCHEMBL31474568 | 0.85 | P4HTM (0.57) | MAP4K4P4HTMP4HA1MIFKDM4E | |
| Hydrochloric Acid SCHEMBL1828697 | 0.85 | P4HTM (0.57) | MAP4K4P4HTMP4HA1MIFKDM4E | |
| SCHEMBL4725410 | 0.84 | MAP4K4 (0.68) | MAP4K4EGLN1KMOPTGS2P4HTM | |
| SCHEMBL2949623 | 0.81 | LDHA (0.61) | MAP4K4KMOP4HTMCNR2P4HA1 | |
| SCHEMBL7946346 | 0.79 | MAP4K4 (0.48) | MAP4K4EGLN1P4HTMP4HA1MIF | |
| SCHEMBL13731115 | 0.79 | P4HTM (0.64) | MAP4K4EGLN1P4HTMP4HA1MIF | |
| SCHEMBL27905615 | 0.77 | KMO (0.58) | MAP4K4EGLN1KMOP4HTMKDM4E | |
| SCHEMBL4781819 | 0.77 | MAP4K4 (0.59) | MAP4K4PTGS2 | |
| SCHEMBL11044929 | 0.76 | MAP4K4 (0.55) | MAP4K4EGLN1KMOPTGS2P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504412-B2 | Imidazopyridine derivatives | BANYU PHARMACEUTICALS, CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20080200494-A1 | Imidazopyridine Derivatives | MSD K.K. (JP) | 2008-08-21 | — | — | US | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200494-A1 | Imidazopyridine Derivatives | MC1R, MC3R, MC5R | MAP4K4 666/4885EGLN1 1113/4885KMO 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.